Physician profile
Phyllis A Gundersen
NPI 1295785608
$710.64
in general payments reported to CMS, 2019-2025
16 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $102 · 2024: $265 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $253.27 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $53.17 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $52.14 | 2024 | Gvoke Hypopen |
| Janssen Scientific Affairs, LLC | $38.54 | 2023 | Xarelto |
| Lilly USA, LLC | $37.23 | 2024-2025 | Jardiance, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $35.76 | 2024-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $34.21 | 2025 | Auvelity |
| Novo Nordisk INC | $33.91 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $31.10 | 2024 | Airsupra |
| Amgen INC. | $27.82 | 2024-2025 | Evenity, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.93 | 2025 | Caplyta |
| Corium, LLC | $21.62 | 2025 | Azstarys |
| Sumitomo Pharma America, INC. | $20.65 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $17.47 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.45 | 2024 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.37 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Gundersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.